Skip to content

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

Pharmacokinetic and Pharmacodynamic Characterization of ALX148, a CD47 Blocker, in Patients with Advanced Malignancy and Non-Hodgkin Lymphoma

Post navigation

Previous: Oral Presentation: A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti-Cancer Antibodies to Bridge Innate and Adaptive Immune Responses for Advanced Malignancy

Next: A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti-Cancer Antibodies to Bridge Innate and Adaptive Immune Responses for Advanced Malignancy

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn Level Access